Novartis CMO John Tsai, MD, said that while the drug didn’t show the benefit the company was hoping for, it helped to improve scientific understanding of COVID-19 and the role of similar drugs.
“There’s still an urgent need for effective ways to combat COVID-19, and we will continue to apply our best scientific minds in support of the global pandemic response,” Dr. Tsai said.
Novartis said it will submit the full results to a peer-reviewed journal soon.
The trial results don’t affect any other trials for Ilaris, including those testing it for non-small cell lung cancer.
Read the full news release here.
More articles on pharmacy:
CVS CEO to step down, hand reins to Aetna chief
Allogene reports patient death tied to its CAR-T drug
Sandoz, Civica Rx ship first drug to US hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
